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Abstract
The evolution of drug resistance is an important process that affects clinical outcomes. Resistance to fluconazole, the most
widely used antifungal, is often associated with acquired aneuploidy. Here we provide a longitudinal study of the
prevalence and dynamics of gross chromosomal rearrangements, including aneuploidy, in the presence and absence of
fluconazole during a well-controlled in vitro evolution experiment using Candida albicans, the most prevalent human fungal
pathogen. While no aneuploidy was detected in any of the no-drug control populations, in all fluconazole-treated
populations analyzed an isochromosome 5L [i(5L)] appeared soon after drug exposure. This isochromosome was associated
with increased fitness in the presence of drug and, over time, became fixed in independent populations. In two separate
cases, larger supernumerary chromosomes composed of i(5L) attached to an intact chromosome or chromosome fragment
formed during exposure to the drug. Other aneuploidies, particularly trisomies of the smaller chromosomes (Chr3–7),
appeared throughout the evolution experiment, and the accumulation of multiple aneuploid chromosomes per cell
coincided with the highest resistance to fluconazole. Unlike the case in many other organisms, some isolates carrying i(5L)
exhibited improved fitness in the presence, as well as in the absence, of fluconazole. The early appearance of aneuploidy is
consistent with a model in which C. albicans becomes more permissive of chromosome rearrangements and segregation
defects in the presence of fluconazole.
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Introduction
Candida albicans is the most prevalent fungal pathogen of humans
and is commonly treated with fluconazole because of its low
toxicity, low cost and oral availability. The acquisition of drug
resistance is an evolutionary process that occurs because
antimicrobials rarely kill an entire population [1]. The survivors
are subject to strong natural selection for resistant phenotypes in
the presence of a drug. The increasing use of prolonged courses of
fungistatic antifungal therapies increases the incidence of acquired
antifungal drug resistance (reviewed in [2–4]). Fluconazole is
especially prone to result in resistance as it is fungistatic, not
fungicidal and the effective size of surviving populations is large.
Furthermore, resistant subpopulations appear to be maintained in
the host, since previously treated patients have a higher incidence
of resistance to subsequent fluconazole treatments [5].
The evolution of drug resistance depends on phenotypic
variability, and the ultimate source of that variability has been
considered to be mutations that alter gene expression or protein
activities (e.g., [6]). Recent studies indicate that copy number
variation (CNV), including short segmental CNV and whole
chromosome aneuploidy, are important contributors to genetic
variability in human diseases, as well as to the acquisition of
resistance to chemotherapeutic agents by tumor cells [7,8].
Indeed, in S. cerevisiae, the increased frequency of CNV and
aneuploidy over point mutations during experimental evolution is
an indication of the fitness benefit these mutations convey [9].
Fungi exposed to antifungal agents also exhibit high levels of
aneuploidy [10–13].
In addition to genetic changes in DNA sequence and/or copy
number, reproductive output, used to estimate fitness, is an
important component of a resistance phenotype [14]. The ability
of a pathogen with an altered genotype to survive in the presence
and in the absence of drug greatly influences the degree to which
that genotype will proliferate in the population and the degree to
which it can be targeted if drug regimens are changed. However,
the fitness effect of CNVs in the presence and absence of drugs has
not been studied systematically. In particular, the dynamics of
aneuploidy acquisition, fixation and change in a population over
the course of physiologically relevant drug treatment have not
been examined.
Molecular mechanisms of resistance to fluconazole are well
documented and include alterations of two general processes. First,
lanosterol 14-alpha-demethylase, which catalyzes a critical step in
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target of the azole drugs and alterations in this enzyme structure or
increases in the level of the protein confer resistance (reviewed in
[4]). Second, drug efflux via ABC transporters (encoded by CDR1
and CDR2) or via the major facilitator superfamily efflux pump
(encoded by MDR1) decreases effective intracellular drug levels,
allowing cells to survive in the presence of higher extracellular
drug concentrations. Increased activity of these processes can be
achieved through point mutations in genes encoding the proteins
[15] or in transcription factors that regulate them [16–18].
Expression levels [19] or physical copy numbers of these genes can
also be increased via genome rearrangements such as whole
chromosome and segmental aneuploidies [11,20].
Alteration in gene copy number is a major mechanism for
environmental adaptation of asexual yeast populations [21,22]. In
C. albicans, karyotype variability appears in many clinical isolates
[23] as well as in some laboratory strains [24,25]. Aneuploidy is
especially common in fluconazole resistant (Flu
R) strains: approx-
imately 50% of Flu
R strains carried a whole chromosome or
segmental aneuploidy, while only 10% of fluconazole sensitive
(Flu
S) strains exhibit any type of aneuploidy [11]. One specific
segmental aneuploidy, i(5L) (an isochromosome composed of two
identical chromosome arms (Chr5L) flanking a centromere),
increases gene copy numbers of Chr5L at least 2 fold relative to
Chr5R, and appears in .20% of drug resistant strains (12/57
strains analyzed) [11], and A.S. and J.B., unpublished data). The
appearance of i(5L) is highly correlated with the appearance of
increased Flu
R, and this Flu
R is primarily due to the presence of
two genes on Chr5L that contribute additively and independently
to Flu
R [20]: ERG11 is located ,150 kb from the left telomere and
TAC1, a transcription factor that activates CDR1 and CDR2
expression [17,26], is located ,48 kb from the centromere.
Despite the high prevalence of CNVs in Flu
R isolates, no
systematic characterization of CNV dynamics has been performed
on isogenic C. albicans strains throughout the course of fluconazole
treatment.
The evolution of drug resistance has been studied by following
patient isolates over time. These studies are useful because they
provide information about the evolutionary pressures occurring in
the patient. For example, data from isolates taken from a patient
that acquired Flu
R have revealed the homozygosis of point
mutations in ERG11 [27] and in TAC1 [26]. We recently found
that i(5L) was acquired twice, in two genetically distinct
bloodstream isolates from an individual patient, and that its
appearance correlated with increases in the fluconazole minimal
inhibitory concentration (MIC) [20], indicating that active changes
in chromosome copy number are an important mechanism for the
evolution of antifungal resistance in the clinical setting. However,
studies of chronological patient samples are limited because the
consecutive events that led to establishment of a specific strain are
only inferred [28].
Experimental evolution permits more direct observation of the
dynamics of genetic and genomic changes in identical starting
populations exposed to a known selective pressure. Multiple,
parallel experiments can be performed with controlled conditions
of population size and selection pressure in an environment which
facilitates sampling of the population throughout the evolutionary
process. In addition, they permit analysis of the fitness conse-
quences of those genetic changes and of the frequency of a given
genomic change in the population. Parallel evolution of similar
genetic changes under identical selection conditions provides
strong evidence that these mutations provide an adaptive
advantage [29]. For example, evolution of E. coli for 20,000
generations resulted in strains with similar expression profiles [30].
Experimental evolution of haploid and/or diploid S. cerevisiae in
limiting nutrient conditions led to amplification of chromosome
regions between highly similar genetic loci [21,31,32], as well as
reproducible segmental aneuploidies that were specific to the
selection environment [29]. In addition, one diploid strain gave
rise to trisomy of three whole chromosomes [29].
In the presence of drug, cells that acquire drug resistance are
generally more fit than the ancestral strain. In the absence of drug,
the relative fitness of these two strains varies [6,33]. In a previous
study, Cowen et al (2000) performed experimental evolution of a
single drug sensitive C. albicans strain, T118, a strain isolated from
an oral swab from a patient that was HIV positive. They used a
single colony to seed a liquid culture for one round of overnight
growth and then divided this culture into 12 independent T118-
derived populations: 6 in the absence of drug (N1–N6) and 6 in the
presence of drug (fluconazole, D7–D12). Serial cultures were
propagated for ,330 generations of growth. Each time a culture
grew, the amount of fluconazole added to each population was
double the MIC. Three independent drug-treated populations
acquired very high levels of Flu
R and we previously found that
i(5L) was present in these three populations (D9-330, D11-330,
and D12-165) [11].
Here we studied the evolutionary dynamics of aneuploidy in
these twelve batch culture lineages by performing genetic sampling
throughout the entire evolution experiment as well as of
individuals within mixed subpopulations at times when gross
chromosomal rearrangements arose. We performed contour-
clamped homogeneous electric field (CHEF) karyotype analysis
followed by Southern hybridization to detect gross chromosomal
rearrangements, along with comparative genome hybridization
(CGH) analysis to detect alterations in chromosome copy number.
In addition, we determined the frequency of genome changes by
analyzing multiple clones from many of the populations. Following
the evolution of initially isogenic populations enabled us to address
several questions about the evolution of aneuploidy in C. albicans:
how early did aneuploidy arise in these populations? What were
the dynamics of aneuploid chromosome acquisition and loss in the
presence and absence of drug selection? Did specific aneuploidies
arise with similar dynamics in different populations? Furthermore,
we performed experiments to ask about the fitness effects of the
aneuploidies in the presence and absence of fluconazole. We found
Author Summary
C. albicans, the most prevalent human fungal pathogen,
acquires resistance to fluconazole by genetic alterations
that often include changes in the number of chromosomes
or chromosome arms (aneuploidy). Here we demonstrate
that chromosomal rearrangements resulting in increased
gene dosage are the predominant means of acquired
resistance to the antifungal drug fluconazole in replicated
experimental populations of C. albicans. A specific
aneuploidy, isochromosome 5L, which is composed of
two copies of the left arm of Chr5, occurs with high
frequency and is detectable soon after fluconazole
exposure. The early appearance of aneuploidy in some
populations is consistent with a model in which C. albicans
becomes more permissive of chromosome rearrange-
ments and segregation defects in the presence of
fluconazole. The results presented here indicate that the
C. albicans genome is highly plastic and imply that
exposure to an antifungal drug induces genome reorga-
nization events, some of which provide a fitness advantage
in the presence of drug.
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populations or parental strain at any time point. Nonetheless, we
found that two specific aneuploid chromosomes, i(5L) and trisomy
of Chr7, were detectable within the first drug-exposed passage of
all three populations that became highly Flu
R. Furthermore,
additional aneuploidies appeared and disappeared over the course
of the experimental evolution. Interestingly, in most cases these
aneuploid cells, which carried almost 20% more total DNA
content than the progenitor cells, had a clear growth advantage in
the presence of fluconazole. Thus, exposure to an antifungal drug
led to positive selection of specific aneuploidies and gross
chromosomal rearrangements.
Results
Karyotype changes are present in early populations that
ultimately evolve high levels of Flu
R
To follow genome dynamics during the evolution of Flu
R under
controlled experimental conditions, we analyzed three indepen-
dent fluconazole treated populations (D9, D11 and D12) that
developed very high levels of Flu
R (MIC peaks of ,96 mg/ml) ([6]
and Figure 1A). We also analyzed six non-drug treated populations
derived from the same progenitor strain. In a previous study, we
detected i(5L) and other aneuploidies in samples with the highest
MIC values from populations that had undergone an estimated
Figure 1. Drug resistance profiles throughout evolution. (A) Populations evolved with fluconazole (D9, D11, and D12) adapted to the drug
and showed increased fluconazole MIC [6]. Populations evolved without fluconazole (N1–N6) show no change in MIC and (B) maintain karyotype
stability. Whole chromosomes were separated by CHEF, stained with Ethidium Bromide (Left) and (C) subjected to Southern hybridization with a CEN5
probe. Lane P, the progenitor strain karyotype.
doi:10.1371/journal.pgen.1000705.g001
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i(5L) in the tested D9 and D11 samples co-migrated with Chr7
(,950 kb), the size expected (,945 kb) for independent i(5L)
composed of two copies of Chr5L plus CEN5. In the D12-165
sample, the extra Chr5L sequences were found in a much larger
band that co-migrated with Chr2 (,2.2 Mb). Southern analysis
demonstrated that this large band was composed of an intact i(5L)
attached through a telomere-telomere fusion to the left telomere of
an intact copy of Chr5 to form an attached isochromosome 5L
(att-i(5L)) [11]. While i(5L) was detected in all three populations,
the dynamics of the appearance of i(5L) and other aneuploidies
was not known. We did not know when it had arisen and whether
or not it had become fixed in the population. Furthermore, while
strains containing i(5L) often carried other aneuploid chromo-
somes as well, it was not clear if those other aneuploidies were
more or less stable than the i(5L) in the populations.
To address questions concerning the dynamics of genome
change in these populations, we analyzed the untreated popula-
tions (N1 through N6) and all of the time points from the three
drug treated populations (D9, D11, and D12) on CHEF karyotype
gels stained with EtBr (Figure 1B and Figure 2A–2C), and then
analyzed them by Southern hybridization with a CEN5 probe
(Figure 1C and Figure 2D–2F), which detects the i(5L) that co-
migrates with Chr7 [11]. In D9, the EtBr-stained karyotypes of
early cultures appeared generally unchanged, other than a minor
change in Chr5 Major Repeat Sequence (MRS) length (A.S. and
J.B., unpublished data) and the appearance of a new band below
Chr4 in three later populations (Figure 2D, arrow, discussed
below). Surprisingly, Southern analysis revealed a band corre-
sponding to the size of i(5L), in all the evolved cultures, including
the ,3.3 generation isolate. However, the intensity of hybridiza-
tion in D9-3.3 was lower than in the other generations (Figure 2D).
Similar results were seen in population D11, except that
hybridization of the CEN5 probe to i(5L) was stronger than in
D9-3.3 (Figure 2E). In the D12 CHEF karyotypes, the acquisition
of the att-i(5L) also was evident within the earliest ,3.3 generation
isolate (Figure 2E and 2F) and the shorter Chr5 homolog (MTLa,
data not shown) ‘disappeared’ at the same time. Importantly, this
att-i(5L) was composed of 3 copies of the MTLa copy of Chr5L
[11]. In contrast, the i(5L) in D9-3.3 and D11-3.3 were composed
of 2 copies of the MTLa copy of Chr5L, indicating that the i(5L) in
D12 arose independently from the i(5L) found in D9 and D11
populations. At later generations 260, 300 and 330, the att-i5L
‘disappeared’ and the MTLa homolog of Chr5 ‘reappeared’. This
is consistent with the idea that two events occurred: an i(5L)
formed from the MTLa homolog of Chr5L and it also became
attached to the shorter homolog of Chr5 to form the att-i(5L).
Later in the evolution of the culture, the i(5L) portion of the att-
i(5L) was lost. Thus, in all three cultures that evolved high levels of
Flu
R, either i(5L) or att-i(5L) was detectable at the earliest sampling
of the cultures.
Importantly, neither i(5L) nor any other gross chromosomal
rearrangement was detected in the progenitor T118 or in
populations that were not treated with drug (Figure 1B and 1C
and data not shown). Furthermore, i(5L) was not detected in early
time points from drug-treated populations that did not develop
high levels of Flu
R (D7, D8 and D10, data not shown). In addition,
populations of T118 progenitor cells plated on fluconazole
concentrations do not contain drug resistant colonies (data not
shown). Taken together with the appearance of two different forms
of i(5L) generated from different MTL alleles, this suggests that the
different forms of i(5L) either arose late during growth of the
original progenitor colony used to seed all 12 cultures or that the
two different isochromosomes arose within the first 24 hours of
drug exposure. In either case, growth in fluconazole was selective
for the i(5L).
While only semi-quantitative, Southern analysis of CHEF gels
suggested that i(5L) may not be present in all cells in some of the
populations such as D9-3.3. To address this issue more directly, we
analyzed individual colonies from a number of the time points, to
ask if the i(5L) was present in each of the progenitor cells that gave
rise to the colonies. Again, CHEF karyotype gels were first
analyzed with EtBr and were then subjected to Southern analysis
using the CEN5 probe. An example of the results for colonies
derived from the D9-3.3 population is shown (Figure 3). Similar
analyses were performed for clones from other populations
(Figures S1, S2, S3) and the results are summarized in Table 1.
As expected for a mixed population of adaptive mutants, 3 of 16
(19%) of the D9-3.3 clones (individual colonies) contained the
i(5L). By the next time point tested (D9-140) all clones carried the
i(5L), indicating that it had become fixed in the population. Of
note, there was heterogeneity in the genome structures of different
clones. For example, the MTLa homolog of Chr5 was lost in clone
D9-3.3-E (Figure 3A and 3B and data not shown).
Despite the higher proportion of i5L at the D11-3.3 time point,
i(5L) did not become fixed as rapidly in this population. After 3.3
doublings, 94% (15 out of 16 clones) contained i(5L); after 50
doublings i(5L) was detected in 73% of the population and by 140
doublings the number decreased to 50% of the clones tested. From
200 doublings on, all clones included an i(5L), suggesting that it
had swept the population after 200 doublings.
In D12-3.3 and D12-50, the att-i(5L) was present in all clones
analyzed, suggesting that it appeared early after drug exposure.
Although CHEF analysis detected a small amount of independent
i(5L) (not attached) in population D12-50 (Figure 2F), it was not
detectable in any of the 10 clones analyzed. Interestingly, the loss
of att-i(5L) appears to have been abrupt as well: it was present in
all of the D12-230 clones (15/15 colonies), but only in 20% of the
D12-260 clones (3/15 colonies).
Frequency of i(5L) correlates with fitness levels
The early appearance of i(5L) in all three populations was
surprising and could be due to several possible mechanisms. First,
it is possible that a subpopulation of the progenitor cells contained
i(5L) and that their increased fitness in the presence of drug caused
them to be rapidly selected [34]. We consider this unlikely because
no i(5L) was detected in early cultures from strains D7, D8 and
D10 under drug selection. In the D8 population, i(5L) never
appeared and in D7 and D10, which acquired transient peaks of
Flu
R (MIC ,4 to 8), i(5L) appeared only in the peak populations
(A.M.S., data not shown). Furthermore, since two types of i(5L)
(attached MTLa/a/a and independent MTLa/a) appeared in
independent populations, both types would have had to be present
in a few cells in the progenitor population and thus each
population would have been heterogeneous for different types of
i(5L).
Second, it is possible that each i(5L) formed during the 24-hour
period of fluconazole stress. Once formed, i(5L) could sweep
through the populations if it provided very strong selective
advantage in the presence of drug, such that clones that had
acquired it out-competed clones within the population that had
not acquired it. To ask if this was the case, we compared the fitness
of clones with or without i(5L) by directly competing each clone
with the drug sensitive ancestor (T118), in the presence and
absence of fluconazole, by measuring the reproductive output of
each competitor in the final mixture (Figure 3C). In the presence
of fluconazole, all clones at generation ,3.3 that contained an
i(5L) exhibited significantly increased fitness relative to the clones
Acquisition of Aneuploidy in Antifungal Drug
PLoS Genetics | www.plosgenetics.org 4 October 2009 | Volume 5 | Issue 10 | e1000705Figure 2. Rapid acquisition of i(5L) occurred in all fluconazole treated populations. (A–C) Whole chromosome CHEF gel analysis of
populations D9, D11, and D12 at generations ,3.3, 50, 140, 165, 200, 230, 260, 300, and 330. (D–F) Southern blot analysis of the CHEF gels using a
CEN5 probe identified both Chr5 homologs as well as either independent i(5L) or att-i(5L) at generation 3.3 in all three populations. The i(5L)
aneuploidy was detected in all subsequent generations of D9 and D11, while the att-i(5L) was lost in D12 after generation D12-260. The CEN5 probe
also hybridized to a novel band at ,1.5 Mb in population D9 (black arrow).
doi:10.1371/journal.pgen.1000705.g002
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were 24%, 46% and 54% more fit than the progenitor,
respectively. In contrast, the non-i(5L) clones (D9-3.3-A and
D11-3.3-D), and the non-drug treated strain (N1-3.3) exhibited
fitness levels that were not significantly different from the
progenitor in the presence of drug. This indicates that i(5L)
confers a strong selective advantage in the presence of the drug.
Furthermore, the growth rate and maximum cell density achieved
by strains containing i(5L) was much higher than that of sibling
strains lacking i(5L) (data not shown). Modeling of cell numbers
indicates that if i(5L) arose within the first 2 hours of fluconazole
exposure, it could have reached .0.2% of the population within
the first growth cycle. Thus, selective advantage alone during
24 hours in fluconazole cannot explain how i(5L) reached levels of
15–100% of the population of ,1610‘6 cells. Importantly, cells
were stored in the selective growth medium (plus glycerol)
immediately following the experiment. We cannot rule out the
possibility that resuscitation of those strains may have involved
some additional selection that allowed cells containing i(5L) to
reach higher proportions of the population.
A third mechanism by which i(5L) may have become a larger
proportion of the population is during subsequent non-selective
propagation of the strains. Such propagation was necessary for
transfer of the strains between labs and for growth and analysis of
Table 1. Percent of cells in a population with i(5L).
Population
Number of
Single colonies
with i(5L)
Total Number
of colonies
analyzed
Percent of Population
with i(5L)
D9-3.3 3 16 19%
D9-140 6 6 100
D9-200 6 6 100
D9-260 9 9 100
D11-3.3 15 16 94%
D11-50 11 15 73
D11-140 3 6 50
D11-200 6 6 100
D11-260 6 6 100
D11-330 6 6 100
D12-3.3 15 15 100%
D12-50 10 10 100
D12-230 15 15 100
D12-260 3 15 20
doi:10.1371/journal.pgen.1000705.t001
Figure 3. Clones at generation 3.3 with i(5L) have a significant fitness advantage in the presence of fluconazole. (A) Karyotype analysis of
five D9-3.3 single colonies by CHEF followed by (B) Southern hybridization to a CEN5 probe. Genetic heterogeneity and clonal interference exists: 3 clones
appear diploid, one clone has i(5L), and one clone is homozygous for Chr5. (C) Fitness competitions were performed, as described in the Materials and
Methods, either in the absence (white bars) or presence (black bars) of fluconazole. Each clone was competed against the same NAT1-marked progenitor
strainandtheaveragerelativefitnesswasdetermined.Errorbarsrepresentthestandarddeviationof3replicateexperiments.Allthreecloneswithi(5L)had
significantly increased fitness in the presence of 0.5 mg/ml fluconazole (asterisks, paired t-test, p#0.05), with no disadvantage in the absence of the drug.
doi:10.1371/journal.pgen.1000705.g003
Acquisition of Aneuploidy in Antifungal Drug
PLoS Genetics | www.plosgenetics.org 6 October 2009 | Volume 5 | Issue 10 | e1000705single colonies for CHEF analysis. We estimate that cells
underwent ,50–70 divisions in the absence of drug prior to
CHEF analysis. In fitness assays conducted under the conditions
used for the evolution experiment (RPMI medium with or without
drug), the D9-3.3, D11-3.3, and D12-3.3 clones that contained the
i(5L) had no significant reduction in fitness relative to the
progenitor in the absence of drug (Figure 3C); furthermore,
D12-3.3 had a significant increase in fitness relative to the
progenitor in the absence of fluconazole and D11 consistently
exhibited a slight increase in fitness under these conditions. Thus
the D12-3.3 population could have easily accumulated more cells
carrying i(5L) during the nonselective growth necessary for CHEF
gel analysis. This may be the case for D11-3.3 as well.
Interestingly, the proportion of cells containing i(5L) in the ‘3.3’
populations reflects the relative fitness advantage of those strains
under non-selective conditions. Thus, we conclude that i(5L) arose
early in all three populations and reached appreciable proportions
of the population during growth in the first cycle of exposure to
fluconazole, but that the very high levels of i(5L) found in the
populations analyzed is due to that selection plus some additional
selective advantage under no drug conditions.
Multiple aneuploidies are evident in drug-evolved
populations
Comparative Genome Hybridization (CGH) performed on a
microarray platform that includes probes covering most ORFs in
the genome provides a comprehensive view of copy number
changes. We used CGH to analyze D9, D11 and D12 populations
as well as a number of single colony clones that previously had
been analyzed by CHEF karyotype gels and Southern hybridiza-
tion (e.g., Figure 3, Table 1). In general, strains carrying the
,945 kb i(5L) on CHEF gels also carried two extra copies of
Chr5L, but there were exceptions. In D11-200, -260 and -330,
there were .5 copies of Chr5L, suggesting that they contained
two copies of i(5L) (4 copies of Chr5L) in addition to the normal
two copies on intact Chr5 homologs (Figure S7).
CGH of D9 strains was consistent with the CHEF karytoype gel
analysis: no i(5L) or other aneuploidies were detected in clone D9-
3.3-A, while i(5L) was detected in clone D9-3.3-D (Figure 4A and
4B). In addition, CGH revealed that Chr3, Chr4 and Chr7 were
trisomic in clone D9-3.3-D. Thus, clone D9-3.3-D included
multiple aneuploidies that were not evident on the CHEF
karyotype gels and its MIC (,3.0 mg/ml), was higher than that
of clone D9-3.3-A (,1.5 mg/ml), which had no obvious aneuploi-
dies. This is consistent with the idea that aneuploidies in D9-3.3-D
(including, but not limited to i(5L)) confer increased drug
resistance. Importantly, the additional whole chromosome triso-
mies did not impair fitness under either the selective or non-
selective growth conditions (Figure 3C) and were observed at
generation 330 (discussed below).
Clones from population D11-3.3 (Figure 4C and 4D) were
generally similar to the clones from population D9-3.3. D11-3.3-A
was trisomic for Chr3 and Chr7 (but not for Chr4) and carried
i(5L). Furthermore, as in D9-3.3 clones, the MIC of strains with
multiple aneuploidies was slightly higher (,2.0 mg/ml) than the
MIC of strains lacking them (,0.5 mg/ml). For D12-3.3, all single
Figure 4. Rapid acquisition of i(5L) coincided with multiple whole chromosome aneuploidies. CGH analysis of single colonies from
populations D9-3.3 and D11-3.3 found that clones were either completely diploid (A,D) and had lower fluconazole MICs, or were aneuploid and had
higher MICs (B,C). Clone D9-3.3-D (B) contains i(5L) and is trisomic for Chrs 3, 4, and 7, while clone D11-3.3-A (C) contains multiple copies of i(5L) andi s
trisomic for Chrs 3 and 7.
doi:10.1371/journal.pgen.1000705.g004
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their growth to sister clones lacking i(5L). Importantly, the degree
to which D9-3.3, D11-3.3 and D12-3.3 had increased fitness in the
presence and absence of drug correlated positively with the
proportion of the population that contained aneuploidies
(Figure 3C and Table 1).
Aneuploidies detected by CGH in evolved populations and their
respective individual clones (Figures S6, S7), are summarized in
Table 2 and revealed several interesting findings: First, the
accumulation of multiple aneuploidies correlated with the highest
MIC. Both D9 and D11 accumulated more aneuploidies than D12
over the evolution experiment and also reached a higher final
MIC (96 mg/ml) than D12 (8 mg/ml). This is consistent with the
idea that aneuploidy can promote evolvability under strong
selection [22,29,35].
Second, whenever i(5L) was present, Chr7 trisomy was also
evident, suggesting that extra copies of Chr7 may enhance the
fitness of strains carrying i(5L). However, loss of i(5L), detected
only in the D12 series, was not accompanied by coincident loss of
Chr7 (described below). Thus, i(5L) and Chr7 do not co-segregate
during all changes in chromosome content.
Third, we observed dynamic appearance and subsequent
disappearance of different clones/aneuploidies: in D9-3.3 the
aneuploid genotype (i(5L) + trisomy of Chrs 3, 4 & 7) was present
in ,15% of the population; in D9-165 trisomy of Chr3 & Chr4
was not evident; in D9-230 and D9-300, a new chromosome band
(Figure 2D arrow, discussed below) appeared and then disap-
peared; and, in D9-330, in addition to i(5L), Chr5R was
monosomic, Chrs4, 6 and 7 were trisomic and Chr3 had a
segmental trisomy. Nonetheless, whole chromosome and segmen-
tal aneuploidies detected in single clones at generation 3.3 were
highly predictive of the aneuploidies detected in the D9 and D11
populations at generation 330. For example, the aneuploid
chromosomes of clone D9-3.3-D (i(5L), Chr3, Chr4, & Chr7)
were present in population D9-330, except that the Chr3 trisomy
became a segmental trisomy. This suggests that, once it becomes
aneuploid, the C. albicans genome is dynamic and continues to
change. Yet, under fluconazole there was strong selective pressure
for a similar repertoire of aneuploidies. Finally, no aneuploidy was
detected in the progenitor strain (T118), in the endpoints of each
N1 population (N1-330 to N6-330), nor in single colonies from
within each endpoint population (N1-330-A to N6-330-A) (Figures
S4, S5). Thus, during extended growth in vitro, in the absence of
selective pressure, the karyotype did not change.
Transient appearance of a supernumerary chromosome
(SNC) is associated with decreased fitness yet higher MIC
relative to the progenitor
A new band with apparent size of ,1.5 Mb appeared in the
later D9 populations (D9-230, D9-260 and D9-300, Figure 2D,
upper arrow) while i(5L) remained detectable in these populations.
Clones from D9-260 grew with two distinct colony size phenotypes
(Figure 5A): small colonies that grew slowly (clones D9-260-a to -e)
and colonies with a wild-type size and growth rate (clones D9-260-
F to -I). CHEF gel analysis indicated that the small colonies
contained the ,1.5 Mb SNC as well as i(5L) while the larger
colonies retained i(5L) only (Figure 5B). CGH analysis of small and
large colonies indicated that both types of colonies contained 2–4
additional copies of Chr5L and were trisomic for Chr7 (Figure 6A
and 6B). In addition, small colony D9-260-a was trisomic for
Chr6. To ask if the ,1.5 Mb SNC included either Chr5R, Ch6
and/or Ch7 DNA fused to Chr5L DNA, we probed Southern
blots of the CHEF with probes from Chr6 (two from 6L and one
from 6R), CEN7, the right arm of Chr5, and MTLa on Chr5L
(probes are listed in Table S1). None of these probes hybridized to
the ,1.5 Mb SNC (Figure 5B and data not shown). This suggests
that neither Chr5R, nor Chr6, nor Chr7 are fused to Chr5L in the
novel SNC.
We then isolated the ,1.5 Mb SNC from the CHEF gel,
labeled it with Cy3 and analyzed the contents of this single
chromosome by CGH [21]. As expected, the band included DNA
from all of Chr5L including CEN5. Strikingly, it also included a
segment of Chr3R beginning just to the left of DYN1 (orf19.5999)
Table 2. C. albicans strains used (ploidy characterized by
CGH).
Stain Name Strain Number Relevant Ploidy
SC5314 YJB2348 Diploid
T118 YJB9613 Diploid
T118-Eno1::NAT YJB10821 Diploid
N1-330 YJB10653 Diploid
N2-330 YJB10654 Diploid
N3-330 YJB10655 Diploid
N4-330 YJB10656 Diploid
N5-330 YJB10657 Diploid
N6-330 YJB10658 Diploid
N1-330-A YJB10881 Diploid
N2-330-A YJB10883 Diploid
N3-330-A YJB10885 Diploid
N4-330-A YJB8741 Diploid
N5-330-A YJB10888 Diploid
D8-330 YJB8734 Diploid
D9-3.3-A YJB10952 Diploid
D9-3.3-D YJB10955 i(5L),Trisomy Chr3, Chr4, Chr7
D9-165 YJB8735 i(5L), Trisomy Chr7
D9-260-A YJB10970 i(5L), additional 5L, Trisomy
Chr6, Chr7
D9-260-B YJB10971 i(5L), additional 5L, Trisomy
Chr6, Chr7
D9-260-B_CHEF
band only
YJB10971-
CHEFband
26Chr5L and 16Chr3R
(orf19.5999- right telomere)
D9-260-F YJB10975 i(5L), Trisomy Chr7
D9-330 YJB8736 i(5L), Monosomy 5R, Trisomy
Chr4, Chr6, Chr7, Segmental
Trisomy Chr3
D11-3.3-A YJB10981 i(5L), Trisomy Chr3, Chr7
D11-3.3-D YJB10984 Diploid
D11-200 YJB10673 26i(5L), Trisomy Chr7
D11-260 YJB10675 26i(5L), Trisomy Chr7
D11-330 YJB8737 26i(5L), Monosomy 5R,
Trisomy Chr7, Segmental
Trisomy and Segmental
Tetraploidy Chr4
D12-165 YJB8738 attached Chr5-i(5L), Trisomy
Chr7
D12-165+100 generations
without Flu selection
YJB10283 Trisomy Chr7
D12-260 YJB8739 Trisomy Chr4, Chr7
D12-330 YJB8740 Trisomy Chr4
doi:10.1371/journal.pgen.1000705.t002
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copy number (because one chromosome is hybridized relative to a
whole genome), the signal from Chr5L was approximately twice as
high as the signal from the Chr3R segment. This is consistent with
the size of the fragment and implies that the ,1.5 Mb SNC is
composed of two copies of Chr5L (most likely organized as an
isochromosome, ,945 kb) attached to a (,600 kb) segment from
Chr3R (5L-CEN5-5L::3(orf19.5999Rtel)). We refer to the
,1.5 Mb SNC as i(5L)-3R.
The detection of a Chr3R segment in the isolated ,1.5 Mb
SNC was surprising since no obvious increase in the number of
Chr3R copies was evident in the whole genome CGH of small
colony D9-260 clones (Figure 6A and Figure S6B). Southern
analysis of whole chromosome CHEF gels confirmed that CDR1,a
gene just to the right of DYN1 and within the Chr3R segment, is
present on the ,1.5 Mb SNC as well as on intact Chr3. and
CDR2, a gene just to the left of DYN1, is not (Figure 5C). A CEN3
probe, located farther to the left of the Chr3R segment breakpoint,
is also absent from the ,1.5Mb SNC (Figure 5C). Consistent with
the fusion of Chr3R to an i(5L), the ,1.5 Mb SNC did not include
an Sfi1 restriction site (Figure S8A). Also, since both the
independent i(5L) and the i(5L)-3R SNC in these clones carry
only the MTLa homolog (Figure S8B), the event that gave rise to
the ,1.5 Mb SNC likely involved a non-reciprocal recombination
event in which one Chr3R segment was copied onto the end of the
i(5L) that was already present in the population.
The stability of the i(5L)-3R SNC was highly variable, with
some small colony clones giving rise to all small colonies and some
giving rise to small and large colonies. CHEF gel analysis indicates
that all of these large colony derivatives had lost the ,1.5 Mb
SNC (Figure S8C). In fact, loss of the SNC occurred in isolate D9-
260-a during subsequent propagation for CHEF analysis (,20
generations in YPD) (Figure S8A, single colony lane ‘‘a’’). These
observations prompted analysis of fitness and chromosome
stability in clones with and without the SNC. The slow growth
of clones containing the ,1.5 Mb SNC is consistent with the idea
that this SNC caused a burden on cell growth. Indeed, it caused a
growth disadvantage in the absence and in the presence of
fluconazole relative to the progenitor strain (Figure 6D). The MIC
of this subpopulation (48–64 mg/ml) accounts for the MIC of the
original D9-260 population (64 mg/ml). Despite the very slow
growth of the small D9-260 clones in the presence of drug, the
large D9-260 clones grew even less well in fluconazole and had a
much lower MIC (8 mg/ml). This implies that the SNC is a
beneficial yet costly mutation (Figure 6D). Consistent with the
observation that the i(5L)-3R SNC in clone D9-260-a was unstable
during culture, a double ellipse of growth formed in the e-strip
assay (Figure 6A, insert) one at 64 mg/ml and the other at 8 mg/
ml. We propose this is due to loss of the SNC during growth of the
colonies on the plate.
Instability of att-i(5L)
In D12, the att-i(5L) was maintained through 230 doublings and
then was quickly lost. CGH analysis of these strains detected the
i(5L) DNA as well as trisomy of Chr7 (Figure 7A). No other
aneuploidies were evident in the strain. Thus, an extra copy of
Chr7 accompanied the acquisition of i(5L) in all three of the
cultures derived from T118 that reached higher MICs (D9, D11
and D12). A drop in MIC accompanied the loss of the att-i(5L),
and the intact MTLa Chr5 homolog, whose mobility was altered
upon att-i(5L) formation, was restored (Figure 8A). A similar loss of
att-i(5L) and restoration of the original Chr5 homolog was seen in
transformants derived from D12-165 (Figure 8B). Importantly, the
drop in MIC upon loss of att-i(5L) and retention of Chr7 trisomy
Figure 5. Southern blot analysis of the ,1.5 Mb SNC. (A) Population D9-260 exhibited colony size variability on YPD plates. (B,C) CHEF/
Southern analysis of single colonies detected a novel ,1.5 Mb SNC in small (lanes a–e) but not in large (lanes f–i) colonies. The ,1.5 Mb SNC
hybridized to CEN5 and Chr3R probe CDR1 (arrows), but not to probes from probes further to the left on Chr3 (CDR2 and CEN3) or from Chr6. Both
small and large colonies maintained independent i(5L) (arrowhead).
doi:10.1371/journal.pgen.1000705.g005
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resistance came from genes on i(5L), rather than from genes on
Chr7. Consistent with this, propagation of D12-165 (att-i(5L) and
Chr7 trisomy) in the absence of drug for over 100 doublings (or
transformation with NAT1 which sometimes led to i(5L) loss)
resulted in a drop in MIC, loss of the att-i(5L) from the population
and retention of Chr7 trisomy (Figure 7D).
In the original study, continued evolution of D12-260 for
another 70 doublings in the presence of fluconazole (D12-330) was
accompanied by loss of Chr7 trisomy, while Chr4 trisomy
remained in the culture (Figure 7C). Loss of the i(5L) and Chr7
trisomy resulted in a drop in MIC from 64 mg/ml to 4 mg/ml.
This residual Flu
R (compared to the progenitor) could be due to
the extra copy of Chr4 or to other mutations accumulated in the
strain during propagation in the presence of the drug.
Discussion
In this study we analyzed changes in genome organization and
copy number that are now recognized as important contributors to
antifungal drug resistance. In vitro analysis of the evolutionary
process in strains with an identical ancestor allowed us to monitor
the events that arise and change over time in parallel populations.
Analysis of multiple clones at each generation allowed us to follow
specific mutations that occurred at each generation and determine
the benefit of those mutations based on their fixation within the
population. Importantly, results from this experimental evolution
study mirror the analysis of clinical Flu
R strains: in both cases
,50% of the cultures (3/6 in this study) exhibited aneuploidy
associated with the acquisition of Flu
R and the presence of i(5L)
correlated with the highest fluconazole MICs. Furthermore, loss of
i(5L) correlated with a drop in fluconazole MIC levels [11,20]. The
most surprising result is the early appearance of cells carrying
multiple aneuploidies including, but not limited to i(5L). Yet
different types of i(5L) were acquired in 3 populations while i(5L)
did not appear early in the other three drug-treated populations.
Importantly, neither i(5L), nor any other aneuploidy, was
detectable in any of the populations that were not exposed to
drug. This suggests that under fluconazole stress, either fluconazole
is a mutagen or C. albicans cells enter a hypermutable state when
exposed to fluconazole [34]. Based on the standard exponential
growth model of cell division, cells carrying i(5L) were inadvertently
enriched during storage and resuscitation of the original isolates (see
Materials and Methods). Nonetheless, the presence of i(5L) in these
populations, irrespective of their prevalence, indicates that they
Figure 6. Supernumerary chromosome i(5L)-3R increases resistance to fluconazole. (A) CGH analysis of small colony D9-260-a detected
,4 additional copies of Chr5L and trisomy of Chr6 and Chr7, while (B) CGH of a large colony D9-260-F identified ,2 additional copies of Chr5L (i(5L))
and Chr7 trisomy. E-test strip assays indicated that the smaller colony MIC (,64 mg/ml) (A, insert) was higher than the larger colony MIC (,8 mg/ml)
(B, insert). (C) CGH analysis of the isolated ,1.5 Mb SNC DNA from D9-260-b. Genes from Chr5L (breakpoint at CEN5) and Chr3R (breakpoint just to
the left of CDR1) are highly overrepresented on the ,1.5 Mb SNC. (D) Fitness assays, of D9-260 clones are consistent with slow growth of both the
small (D9-260-a) and larger (D9-260-F) colony clones relative to the progenitor, suggesting that the population has accumulated a large number of
mutations. Nonetheless, small colony clones containing the ,1.5 Mb SNC were slightly more fit in the presence of fluconazole (black bars, ,128 mg/
ml, twice the MIC of the experimental population D9-260) than clones that did not carry the SNC. Fitness of the aneuploid strains was not reduced
significantly in the absence of fluconazole (white bars). Asterisks indicate fitness levels that are significantly different from the progenitor strain.
doi:10.1371/journal.pgen.1000705.g006
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increasingly prevalent during propagation in drug.
How does aneuploidy arise so rapidly?
i(5L) was detectable by CHEF in all three populations after one
24-hour passage in fluconazole. During this time the population
had undergone an average of 3.3 doublings in the presence of
fluconazole. Based on the exponential growth rate model
(Materials and Methods) we assume that i(5L) arose early after
exposure to fluconazole although we cannot rule out the possibility
that a very small number of i(5L) cells existed in the progenitor
culture. If i(5L) appeared early after exposure to fluconazole, it
would support the model that stress-induced mutagenesis may
operate in C. albicans [34]. Consistent with this, stress response
signaling through Hsp90 and/or calcineurin is required for
fluconazole tolerance [36–38]. Alternatively, fluconazole may
function (directly or indirectly) as a mutagen: it has been reported
to be clastogenic in mouse bone marrow cells [39] and causes
significantly increased levels of loss of heterozygosity in C. albicans
(A. Forche and JB, in preparation).
The frequency with which C. albicans undergoes major
chromosome rearrangements in fluconazole is apparently higher
than the frequency of such events in S. cerevisiae haploid or diploid
cells [40]. One explanation offered for the plasticity of the C.
albicans genome is that it is not subject to the constraints imposed
by meiotic segregation and thus it can retain detectable genome
rearrangements that would be lost in organisms that undergo
meiosis. Alternatively, C. albicans may lack some cell cycle
checkpoints that prevent aneuploidy in other organisms, or it
may have an active mechanism to induce concerted chromosome
changes like those seen during the parasexual cycle [41]. Whatever
the mechanism, it is becoming increasingly clear that aneuploidies
are more prevalent than originally thought. For example, ,8% of
the original S. cerevisiae deletion collection contained aneuploidies,
most of them segmental [42]. Furthermore, in the presence of
strong selective pressure, S. cerevisiae myo2D cells with defects in
cytokinesis evolved alternative mechanisms of cell division via the
acquisition of aneuploidies for specific sets of chromosomes [22].
Similarly, whole chromosome trisomy and higher copy aneuploi-
dies were detected more frequently in diploid than haploid S.
cerevisiae cells evolved under nutritional stresses [29]. Thus, while
the frequency of aneuploidy in C. albicans (a diploid) is high, S.
cerevisiae diploids also undergo similar types of events when placed
under selection pressure. The lack of detectable aneuploidy in
untreated cells (Figures S4, S5) and detection of high rates of
aneuploidy in drug treated cells ([11] and this study), as well as in
strains isolated from patients [20] or from animals [43] suggests
that C. albicans is exposed to constant selective pressure when it is
propagated in mammalian hosts. We suggest that this selective
pressure may be even stronger when C. albicans is exposed to
antifungal drugs within the mammalian host.
Variations on Chr5L geometry and copy number
Chr5L appeared in the evolved strains as an independent
chromosome of ,945 kb throughout the experiment in two of the
cultures (D9 and D11), as an i(5L) attached to a full length Chr5
Figure 7. Changes in aneuploid chromosomes are common during adaptation to fluconazole. Population D12 underwent drastic
changes in aneuploid chromosome number, which indicates that clonal interference was high, and coincides with a fluctuation in fluconazole MIC.
(A) D12-165 has att-i(5L) and is trisomic for Chr7, (B) D12-260 lost the att-i(5L) and gained Chr4 trisomy, and (C) D12-330 lost the Chr7 trisomy, but
maintained the Chr4 trisomy. (D) Population D12-165 was passaged for an additional ,100 generations in the absence of fluconazole and it lost the
att-i(5L) aneuploidy, but maintained the Chr7 trisomy.
doi:10.1371/journal.pgen.1000705.g007
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populations. Chr5L copy number also varied in these strains,
irrespective of geometry. For example, multiple copies of
independent i(5L) were present in D11 cells (Figure S7); CGH
estimates approximately 6 copies of Chr5L. Similarly, D9-260
clones contain Chr5L sequences on 4 different chromosomes with
3 different geometries: intact Chr5 (2 copies), i(5L), and the i(5L)-
3R SNC.
In D12, att-i(5L), which includes centromere-to-centromere and
telomere-to-telomere orientations of Chr5L, was acquired early
and was maintained for over 200 doublings. This structure is
potentially dicentric, however micrococcal nuclease digestion
studies suggest that one of the three copies of CEN5 in the strain
is not packaged into centromeric heterochromatin (Carrie Ketel,
unpublished data) and thus is not functional. We presume this is
the CEN5 DNA on the i(5L) portion of att-i(5L) since, once
detached (in D12-260), this DNA is not stably maintained
(Figure 8). In addition, in the D9 culture the i(5L)-3R SNC
appeared in a subpopulation of cells and was maintained in the
population for 70 doublings (D9-230 through D9-300).
Chr5 is naturally heterozygous, because it carries the mating
type-like locus MTL.A nMTLa probe hybridized to att-i(5L) while
an MTLa probe did not, implying that att-i(5L) includes three
copies of the Chr5L homolog that carries MTLa. In contrast, the
i(5L) in both D9 and D11 isolates as well as the i(5L)-3R SNC
hybridized to MTLa and not to MTLa. Thus, independent i(5L) as
well as attached i(5L) derivatives can form from either Chr5
homolog, yet all copies of i(5L) within a single cell contain the
same MTL allele. Importantly, because each isochromosome is
homozygous for one MTL allele, the mechanism of isochromo-
some formation likely involves gene conversion or break-induced
replication rather than a reciprocal recombination event between
two copies of Chr5. Furthermore, in contrast to a previous study in
which MTL homozygosity was associated with Flu
R [44], here,
MTL heterozygosity was maintained throughout all three
evolution experiments. Rather, extra copies of Chr5L (and thus
of MTL) correlated with increased Flu
R, most likely due to the
additional copies of ERG11 and TAC1 that contribute indepen-
dently and additively to Flu
R [20].
Other aneuploidies in Flu
R strains
In addition to Chr5L aneuploidy, increased gene copy numbers
of chromosomes 3, 4, 6, and 7 were found. Multiple genes known to
be important for Flu
R are found on these chromosomes: The
segmental trisomy of Chr3 in strain D9-330 (Figure S6) and Chr3R
segment attached to i(5L) on the i(5L)-3R, includes CDR1, which
encode the major ABC-transporter important for Flu
R [45,46], as
well as MRR1, which encodes a transcription factor that up-
regulates MDR efflux pumps [18]. MDR1 is found on Chr6.
Increased gene copy number of Chr3 and/or Chr6 is likely the
reason that MDR1 is expressed at increased levels in this strain [28].
Additionally, Chr4 copy number was increased in isolates from all
three series: D9-3.3-D, D9-330, D12-260 and D12-330 exhibited
Chr4 trisomy, and a segmental trisomy of Chr4 in D11-260 was
amplified to even higher levels in D11-330. NCP1, which encodes
NADPH-cytochrome P450 reductase and is a co-factor of Erg11p
(the target of fluconazole) in sterol 14 alpha-demethylation in
ergosterol biosynthesis, is on Chr4 within the most amplified region
Figure 8. Transformation of att-i5L results in loss of i(5L) and retention of the intact Chr5 portion. (A) Strain D12-165 contains an att-i(5L)
chromosome with two CEN5 structures (top) and one normal Chr5 homolog (bottom). Transformation was used to disrupt orf19.1963 on Chr5L with
the NAT1 marker. There are 4 existing orf19.1963, three on the att-i(5L) (I, II, III) and one on the full-length Chr5 homolog (IV). (B) CHEF/Southern blot
analysis of 13 NAT1 positive transformants indicates that in all but 3 cases the NAT1 insertion occurred on the att-i(5L) at any locus I-III. In the
remaining 3 transformants, NAT1 insertion occurred at locus III and coincided with detachment of the i(5L) and reformation of the independent Chr5
homolog. This same phenomenon was observed during the original D12 evolution experiment.
doi:10.1371/journal.pgen.1000705.g008
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may provide increased levels of Flu
R because of the increased levels
of NCP1. Additional genes on Chr4 that might affect Flu
R included
ERG8, ERG27 and ERG251, which are all involved in ergosterol
biosynthesis. ERG251is upregulatedinresponseto atleastoneazole
drug, ketoconazole [47], but it is not known if increased numbers of
these genes contribute to drug resistance. Thus, several of the
aneuploid chromosomes that became prevalent in the drug treated
populations carry genes that have already been shown to be
important for increased resistance to fluconazole.
Aneuploidy in C. albicans, as in cancer cells, does not
have a high fitness cost
Malignant cancer cells exhibit unrestricted growth and high
levels of aneuploidy and polyploidy. Yet most aneuploid S. cerevisiae
strains exhibit growth defects under non-selective conditions [48].
This raises an important conundrum: How is it that aneuploidy in
cancer cells does not restrain growth, yet aneuploidy in model
organisms does? In stark contrast, aneuploidy in C. albicans, like
aneuploidy in cancer cells, does not appear to have a high fitness
cost. All aneuploidies reported here all were detectable after
passage for $70 generations in non-selective medium (YPD).
Other Flu
R strains also have been propagated extensively under
non-selective conditions without loss of i(5L). C. albicans aneuploi-
dies are usually increased copies of whole chromosomes whereas S.
cerevisiae aneuploidies that arise in haploid cells under selection are
primarily shorter segmental aneuploidies [21,29,32]. As an
obligate diploid, C. albicans may be better able than haploids to
tolerate the acquisition of an extra chromosome (50% vs 100%
increase in copy number, respectively). Accordingly, S. cerevisiae
diploids exhibit higher rates of aneuploidy under strong selection
[29]. An argument against this simple model is that mice carrying
specific trisomies exhibit reduced fitness [49], however we cannot
rule out the possibility that some aneuploidies or combinations of
aneuploid chromosomes provide a selective advantage under stress
conditions that were not tested in these experiments [50]. The
concerted appearance of i(5L) and Chr7 trisomy are consistent
with such an idea. We suggest that the acquisition of aneuploidy
may be a general mechanism for the rapid evolution of genome
change in response to severe stress conditions in C. albicans. At least
in C. albicans, aneuploidy appears to arise frequently and is well
tolerated, especially in cells responding to physiologically relevant
concentrations of fluconazole. Thus, C. albicans and its response to
fluconazole, may be an excellent model system for studying the
molecular mechanisms that mediate genome changes that occur in
mammalian cells in response to carcinogens.
Materials and Methods
Strain propagation and single-colony analysis
All populations were stored during the initial evolution
experiment by freezing in growth medium plus 15% glycerol.
These populations were revived by streaking to YPD, transferred
between labs on filter paper, revived on YPD, stored in YPD+15%
glycerol as a mixed population and then analyzed by CHEF and
CGH, a process that involved ,50–70 generations of growth on
rich medium that did not contain fluconazole. For single colony
analysis, clones were derived from a population plated on YPD
directly from 280uC storage. After two days at 30uC single
colonies were picked into 5 mL YPD liquid and grown up
overnight also at 30uC. Liquid cultures were used to make CHEF
agarose plugs (1% low melt agarose), gDNA for CGH or PCR
analysis, and were again saved in 15% glycerol at 280uC. When
variation in colony size morphology was observed after plating on
YPD, multiple single colonies of each type were analyzed.
Measurement of Relative Fitness. Fitness of isolates from
the experimental populations was determined by placing each
isolate in direct competition with the progenitor, genetically
marked with resistance to nourseothricin (NAT1). The progenitor
was marked by C-terminally tagging ENO1 with GFP using a
NAT1 selectable marker. The tagging construct was amplified by
PCR with primers (Table S1) oLC597 and oLC596 from plasmid
pMG2021 [20] and transformed into C. albicans following standard
protocols. Transformants were tested for proper integration of the
marker by PCR amplification with primers oLC598 and oLC600
as well as with primers oLC599 and oLC601. There was no
significant difference in fitness between the marked and unmarked
progenitor. Competition experiments were conducted in triplicate
both in the presence and in the absence of fluconazole, essentially
as described [33]. All competitions were conducted in the same
medium as used for the evolution experiment [6], RPMI 1640, at
30uC. For the competitions that were conducted in the presence of
drug, the concentration of fluconazole used was twice the most
recently measured MIC of the experimental population. The
competing populations were first conditioned by growing each
competitor from the frozen archive separately overnight in RPMI
1640 medium. Cell counts of the overnight cultures, performed
with a hemocytometer, were used to prepare a competition mix
containing approximately equal concentrations of the two
competitors. One hundred microliters of the competition mix
was used to inoculate 9.9 ml of fresh medium (with or without
fluconazole), and the competitors were allowed to grow together
for 24 hours. Initial and final densities of each culture were
determined by colony counts from dilution plates on yeast extract
peptone dextrose (YPD) medium. The initial and final densities of
each competitor were determined by replica plating the dilution
plates onto YPD+NAT; under these conditions, only the
genetically marked progenitor is able to grow. Fitness was
estimated as the difference in number of doublings of the two
competitors (evolved population minus the genetically marked
progenitor), standardized by the total number of doublings in the
competition assay, as described [33].
Comparative Genome Hybridization
CGH analysis was performed as described previously using
arrays produced in house [25]. The same reference control strain,
SC5314, was used for all arrays in this paper. Multiple control
hybridizations of SC5314 versus itself were performed and a
representative example is provided in Figure S2A. Genomic DNA
was isolated from cells grown in YPD and was RNaseA treated.
3 mg of DNA was digested with HaeIII for 3–4 hours, purified, and
then labeled with Cy3-dUTP (strain of interest) or Cy5-dUTP
(SC5314) (Pharmacia/Amersham) using the BioPrime Array CGH
labeling Module (Invitrogen). Labeled DNA was purified on a
Microcon 30 filter (Millipore), mixed in a 1:1 ratio, and applied to
the array for a 16-hour hybridization. Fluorescence intensity ratios
(mean log2 values) were obtained and analyzed using GenePixPro
5.1 and GeneTraffic 3.1. A Matlab program was used to plot all
log2 data as a function of chromosomal location [25]. The CGH
array data are listed in GEO, the Gene Expression Omnibus, as
series ‘‘CGH analysis of Candida albicans strains after in vitro
evolution in the presence or absence of fluconazole’’ with
accession number GSE16423.
CHEF and SfiI digestion
Preparation of cells for CHEF analysis was performed as
described previously [25]. Briefly, cells are grown up overnight in
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times with 50 mM EDTA. Cells are suspended in 1% low melt
agarose and then treated with BME and with Proteinase K
solutions. Whole chromosome separation was performed on a
BioRad CHEF-DR III with the following program: 60- to 120-s
switch, 4.5 V?cm21, 120uangle, for 36 hours, followed by a 120-
to 300-s switch, 6.0 V?cm21, 120uangle, for 12 hours. SfiI
digestion of CHEF gel plugs was performed as described
previously [11] and separation of these large chromosome
fragments was done with the following program: 7- to 100-s
switch, 4.5 V?cm21, 120uangle, for 21 hours, followed by 80- to
400-s switch, 3.5 V?cm21, 120u angle, for 21 hours. CHEF gels
were stained with Ethidium bromide and transferred to Magna-
charge membranes for Southern blot analysis.
CHEF–Southern blot analysis
All Southern blots were performed with DIG labeled probes
(Roche) as described previously [25]. Probes were constructed by
PCR using DIG-11-dUTP nucleotides (according to the manu-
facturer’s instructions) and primers that are listed in Table S1.
CGH analysis of an isolated CHEF band
Isolation, labeling and hybridization of the ,1.5 Mb SNC was
performed based on the PFGE-array protocol developed by
Maitreya Dunham (http://dunham.gs.washington.edu/protocols.
shtml). A whole-chromosome CHEF gel wasrun as described above
with 5 lanes of strain YJB10971. The gel was stained with EtBr and
the band representing thenovel ,1.5 Mb SNCwasexcised from all
5 lanes.The gel pieceswereincubated twice for 1 hour in4 volumes
water and then incubated in 16HaeIII buffer (Roche) for 1 hour.
Fresh 16HaeIII buffer and 5 ml HaeIII enzyme (10 units/ml, Roche)
wereadded and incubatedovernightat37uC.DNAwaselutedfrom
the gel slice and precipitated with salt and isopropanol. DNA was
quantitated using a Nanodrop spectrophotometer and 700 ng of
DNA was labeled with Cy3 (as described above), mixed with 700 ng
of Cy5-labeled gDNA from SC5314 (as described above), and
hybridized to a whole genome microarray.
Fluconazole E-test
Cells were grown to mid-log phase, washed in 0.85% NaCl, and
diluted to an OD600 of 0.01. 200–250 ml of cells were plated on
Casitone-agar plates using glass beads and allowed to dry for 15–
30 minutes before applying a fluconazole E-test strip (0.016–
256 mg/ml, AB Biodisk). Plates were incubated at 30uC for
48 hours and the MIC was determined as the first growth-
inhibition ellipse.
Exponential growth rate modeling and freeze-thaw
analysis
Doubling times were determined by growing mixed populations
as well progeny of colonies that contained or did not contain i(5L)
in RPMI or RPMI with fluconazole at 0.5 mg/ml, 35uC or in YPD
medium at 30uC and at 35uC. D9-3.3-D strains (carrying i(5L))
have doubling times of ,138 min (+/210 min) in 0.5 mg/ml
fluconazole, and thus could have divided up to 10.4 times in
24 hours. In contrast, the progenitor strain (without i(5L)) had a
doubling time of ,126 min (+/29 min) in 0.5 mg/ml fluconazole;
these cells consistently divided twice and then stopped dividing.
Similar results were seen when T118 progenitor cells were grown
in fluconazole and analyzed by time-lapse microscopy. Modeling
of the exponential growth phase in the presence of drug based on
these data indicates that if i(5L) cells divided once every
,2.3 hours (138 min), and the non-i(5L) cells divided only twice
in the 24 hour period, and if ,1610‘5 cells/ml were used to start
the 24 hour culture (a number that was determined by measuring
cell number after preparing starter cultures using conditions
identical to those used in the original experiment [6]. If we assume
one i(5L) cell appeared within first 1–2 hours after culture dilution
into RPMI + fluconazole, that cell could have reached ,0.3% of
the culture after 24 hours. Because cells were stored in medium
containing fluconazole, cells would have remained under selective
pressure when resuscitated if residual drug remained active in the
stored cultures and was not diluted upon streaking of cells from the
frozen stock vial. In this case, cells containing i(5L) could have
reached 15–20% of the culture over the next 16 hours of growth,
based on the assumptions about growth rates as detailed above.
We performed several assays to determine if D9-3.3-D cells
(with i(5L)) have any growth advantage on YPD media. We mixed
progenitor and D9-3.3-D cells in a 1:1 mixture and a 1:99 (i(5L) to
progenitor) mixtures. The mixtures were plated on YPD before
freezing, after one freeze-thaw, and after three freeze-thaw cycles.
In none of these experiments did D9-3.3-D cells have a growth
advantage relative to the progenitor.
Supporting Information
Figure S1 Single colony karyotype analysis of parental strain
T118 and D9 populations. CHEF gel analysis followed by
hybridization of the Southern blot with a probe to CEN5 revealed
that all single colonies derived from T118 had the same karyotype
including two, separable Chr5 homologs. CHEF/Southern
analysis of single colonies from generations D9-3.3, D9-140, D9-
200, and D9-260 identified i(5L) (arrowhead) in some or all of the
clones analyzed. In D9-260, an additional ,1.5 Mb SNC
hybridized to CEN5 (arrow).
Found at: doi:10.1371/journal.pgen.1000705.s001 (7.16 MB TIF)
Figure S2 Single colony karyotype analysis of D11 generations
D11-3.3, D11-50, D11-140, D11-200, D11-260, and D11-330.
CHEF gel analysis followed by Southern blot with a probe to
CEN5 shows that the percentage of clones within each population
that carried i(5L) (arrowhead) varied from 50% to 100% during
the evolution experiment (summarized in Table 1).
Found at: doi:10.1371/journal.pgen.1000705.s002 (10.04 MB
TIF)
Figure S3 Single colony karyotype analysis of D12 generations
D12-3.3, D12-50, D12-230, and D11-260. CHEF gel analysis
followed by Southern blot with a probe to CEN5 shows that the
percentage of clones within each population that carried the att-
i(5L) (arrowhead) varied from 20% to 100% during the evolution
experiment (summarized in Table 1).
Found at: doi:10.1371/journal.pgen.1000705.s003 (7.80 MB TIF)
Figure S4 Comparative genome hybridization of (A) the
ancestral strain T118, (B) the NAT1-marked clone of T118 used
for all fitness competitions, (C) population N1-330, (D) population
N2-330, (E) population N3-330, (F) population N4-330, (G)
population N5-330, (H) population N6-330. No aneuploidy was
detected in these populations.
Found at: doi:10.1371/journal.pgen.1000705.s004 (4.78 MB TIF)
Figure S5 Comparative genome hybridization of the reference
control SC5314 versus SC5314 (A) and of single colonies from
populations: (B) N1-330, (C) N2-330, (D) N3-330, (E) N4-330, and
(F) N5-330. No aneuploidy was detected in these clones.
Found at: doi:10.1371/journal.pgen.1000705.s005 (3.66 MB TIF)
Figure S6 Comparative genome hybridization of D9. (A) D9-165
contains i(5L) and Chr7 trisomy, (B) in clone D9-260-b the i(5L) with
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330 has i(5L), trisomy of Chr4, Chr6, and Chr7, Chr5 monosomy,
and a small increase in copy number on the right arm of Chr3 (at the
same breakpoint found on the i(5L)-3R chromosome, asterisk).
Found at: doi:10.1371/journal.pgen.1000705.s006 (5.42 MB TIF)
Figure S7 Comparative genome hybridization of aneuploid D11
populations. All 3 populations, (A) D11-200, (B) D11-260, and (C)
D11-330 have the i(5L) and are trisomic for Chr7. These
populations also have increased copy numbers of i(5L), ,2 copies
per cell, based on Log2 values (Average Log2 values of Chr5L
from two arrays 1.04+/20.01, compared to the Average Log2
value of trisomic Chr7 from these same arrays of 0.41+/20.09).
D11-260 has a segmental trisomy on Chr4 that either gets further
amplified or becomes fixed in the population, such that by
generation 330 the region is highly anueuploid: it includes three
copies of the entire right arm of Chr4 and at CEN4 there is a
transition to more than four copies of part of the left arm of Chr4.
This amplified region includes NCP1, which encodes NADPH-
cytochrome P450 reductase and is a co-factor of Erg11p. Finally,
in population D11-300, Chr5R is monosomic.
Found at: doi:10.1371/journal.pgen.1000705.s007 (5.51 MB TIF)
Figure S8 Further characterization of the i(5L)-3R SNC. (A)
CHEF gel analysis of SfiI digested chromosomal DNA followed by
Southern hybridization to a CEN5 probe identified three bands
(diagramed in D): the centromere-containing 5M band from intact
Chr5 (,750 kb), the full-size i(5L) (,945 kb), and the full-size
SNC (,1.5 Mb). Hybridization with a probe to the right arm of
Chr5 only detects the ,750 kb 5M band (right panel). (B) The
i(5L)-3R SNC and the independent i(5L) in D9-260 colonies both
hybridize to the MTLa allele, and not to the MTLa allele. The
same SfiI-digested CHEF/Southern from (A) was probed with
MTLa (left panel) and with MTLa (right panel). Bands represent-
ing i(5L)-3R, independent i(5L), and the SfiI-digested Chr5M are
indicated. (C) The small colony phenotype of D9-260 is due to the
presence of i(5L)-3R. Ethidium Bromide-stained CHEF gel of
single colonies derived from either a small (sm) or large (LG)
colony from the D9-260-b population. CHEF gel plugs were
prepared from a small colony that gave rise to another small
colony (smRsm), a small colony that gave rise to a large colony
(smRLG), or a large colony that gave rise to another large colony
(LGRLG). Only small colonies maintained the i(5L)-3R SNC,
while large colonies derived from the small colonies had lost the
chromosome. (D) Diagram of a full-length Chr5 homolog
depicting the location of the CEN5 probe, the Chr5R probe
and the sole SfiI restriction site, the digested ,750 kb fragment
from Chr5, the i(5L) lacking any SfiI sites and the ,1.5 Mb SNC
composed of 2 arms of Chr5L, one CEN5, and part of Chr3R,
which also has no SfiI sites.
Found at: doi:10.1371/journal.pgen.1000705.s008 (3.46 MB TIF)
Table S1 Probes and primers used in this study.
Found at: doi:10.1371/journal.pgen.1000705.s009 (0.13 MB
DOCX)
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